Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Work In Process data on file, last reported at $33.0 million in Q1 2026.

• Work In Process for Q1 2026 came in at $33.0 million, up 44.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.0 million (up 44.02% YoY), and the FY2025 annual result was $27.0 million, up 22.73% from the prior year.
• Work In Process rose to $33.0 million in Q1 2026 per RARE's latest filing, from $27.0 million in the prior quarter.
• Over five years, Work In Process peaked at $33.0 million in Q1 2026 and troughed at $12.0 million in Q1 2022.
• A 5-year average of $20.9 million and a median of $19.8 million in 2025 frame the typical range for Work In Process.
• The sharpest annual moves came in 2022 and 2025: Work In Process soared 76.75% in 2022, then dropped 21.77% in 2025.
• A 5-year view of Work In Process shows it stood at $17.5 million in 2022, then advanced by 7.85% to $18.9 million in 2023, then grew by 16.66% to $22.0 million in 2024, then advanced by 22.73% to $27.0 million in 2025, then advanced by 22.22% to $33.0 million in 2026.
• Business Quant data shows RARE's Work In Process at $33.0 million in Q1 2026, $27.0 million in Q4 2025, and $29.2 million in Q3 2025.